StudyFinder

Evaluation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKi) resistance in the tumor tissue of Non-small cell lung cancer (NSCLC) patients

Status: Recruiting

This study is about discovering how Non-small cell lung cancer becomes resistant to EGFR TKI targeted therapy in order to predict and prevent this cancer from not responding to treatment.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Age 18-85 years
• confirmed advanced adenocarcinoma of the lung
• identified EGFR mutation
• treatment with osimertinib
Exclusion Criteria:

• radiation or other drug treatments other than osimertinib
Conditions:

Cancer

Keywords:

lung cancer

Study Contact: Alyssa Pecoraro - pecor029@umn.edu
Principal Investigator: Luke Hoeppner
IRB Number: STUDY00023467

Back